GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SQZ Biotechnologies Co (OTCPK:SQZB) » Definitions » Beneish M-Score

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Beneish M-Score : 0.57 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is SQZ Biotechnologies Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.57 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for SQZ Biotechnologies Co's Beneish M-Score or its related term are showing as below:

SQZB' s Beneish M-Score Range Over the Past 10 Years
Min: -3.82   Med: -2.33   Max: 0.57
Current: 0.57

During the past 5 years, the highest Beneish M-Score of SQZ Biotechnologies Co was 0.57. The lowest was -3.82. And the median was -2.33.


SQZ Biotechnologies Co Beneish M-Score Historical Data

The historical data trend for SQZ Biotechnologies Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQZ Biotechnologies Co Beneish M-Score Chart

SQZ Biotechnologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
- - - -1.89 -2.77

SQZ Biotechnologies Co Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.83 -2.77 -1.27 -0.78 0.57

Competitive Comparison of SQZ Biotechnologies Co's Beneish M-Score

For the Biotechnology subindustry, SQZ Biotechnologies Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQZ Biotechnologies Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's Beneish M-Score falls into.



SQZ Biotechnologies Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of SQZ Biotechnologies Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 4.5893+0.892 * 0.5711+0.115 * 0.3399
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3233+4.679 * 0.513865-0.327 * 1.882
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0.178 + 0 + 12.018 = $12.20 Mil.
Gross Profit was 0 + 0.178 + 0 + 12.018 = $12.20 Mil.
Total Current Assets was $12.09 Mil.
Total Assets was $29.79 Mil.
Property, Plant and Equipment(Net PPE) was $15.40 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.45 Mil.
Selling, General, & Admin. Expense(SGA) was $20.98 Mil.
Total Current Liabilities was $8.83 Mil.
Long-Term Debt & Capital Lease Obligation was $19.08 Mil.
Net Income was -23.639 + -16.77 + -17.687 + -13.547 = $-71.64 Mil.
Non Operating Income was -7.685 + -0.002 + 0.063 + -4.992 = $-12.62 Mil.
Cash Flow from Operations was -14.532 + -15.27 + -23.772 + -20.76 = $-74.33 Mil.
Total Receivables was $0.00 Mil.
Revenue was 3.13 + 3.008 + 2.869 + 12.35 = $21.36 Mil.
Gross Profit was 3.13 + 3.008 + 2.869 + 12.35 = $21.36 Mil.
Total Current Assets was $87.34 Mil.
Total Assets was $154.85 Mil.
Property, Plant and Equipment(Net PPE) was $64.91 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.01 Mil.
Selling, General, & Admin. Expense(SGA) was $27.76 Mil.
Total Current Liabilities was $25.26 Mil.
Long-Term Debt & Capital Lease Obligation was $51.82 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 12.196) / (0 / 21.357)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(21.357 / 21.357) / (12.196 / 12.196)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (12.087 + 15.396) / 29.788) / (1 - (87.337 + 64.906) / 154.854)
=0.07738 / 0.016861
=4.5893

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=12.196 / 21.357
=0.5711

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(11.005 / (11.005 + 64.906)) / (11.452 / (11.452 + 15.396))
=0.144972 / 0.426549
=0.3399

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(20.98 / 12.196) / (27.764 / 21.357)
=1.720236 / 1.299995
=1.3233

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((19.075 + 8.832) / 29.788) / ((51.823 + 25.261) / 154.854)
=0.936854 / 0.497785
=1.882

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-71.643 - -12.616 - -74.334) / 29.788
=0.513865

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

SQZ Biotechnologies Co has a M-score of 0.57 signals that the company is likely to be a manipulator.


SQZ Biotechnologies Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of SQZ Biotechnologies Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SQZ Biotechnologies Co (SQZ Biotechnologies Co) Business Description

Traded in Other Exchanges
N/A
Address
200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
Executives
Richard Capasso officer: See Remarks C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marshelle Smith Warren officer: Chief Medical Officer C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Klavs F. Jensen director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Amy W Schulman director, 10 percent owner PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Bernard Coulie director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Vink Patrick V.j.j. director ETZELSTRASSE 20, 8707 UETIKON AM SEE V8 V8
Temasek Holdings (private) Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
American International Group, Inc. 10 percent owner 1271 AVE OF THE AMERICAS, FL 37, NEW YORK NY 10020-1304
Polaris Entrepreneurs' Fund Vii, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Arny Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016 U/d/t Dated December 29, 2016 10 percent owner C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marc Elia director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Armon Sharei director, officer: President and CEO C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Headlines

From GuruFocus

SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

By Business Wire Business Wire 07-11-2022